OverviewSuggest Edit

MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.

TypePublic
Founded2000
HQSan Diego, US
Websitemeipharma.com

Latest Updates

Employees (est.) (Jun 2019)40(+25%)
Job Openings7
Revenue (FY, 2020)$28.9 M(+489%)
Share Price (Sept 2020)$3.5 (+9%)
Cybersecurity ratingBMore

Key People/Management at MEI Pharma

Daniel Gold

Daniel Gold

President & Chief Executive Officer
Christine A. White

Christine A. White

Non-Executive Chairman
Robert Mass

Robert Mass

Chief Medical Officer
Charles V. Baltic

Charles V. Baltic

Non-Executive Director
Brian Drazba

Brian Drazba

CFO
Kevan Clemens

Kevan Clemens

Non-Executive Director
Show more

MEI Pharma Office Locations

MEI Pharma has an office in San Diego
San Diego, US (HQ)
3611 Valley Centre Dr #500
San Diego, US
11455 El Camino Real #250
Show all (2)

MEI Pharma Financials and Metrics

MEI Pharma Revenue

MEI Pharma's revenue was reported to be $28.91 m in FY, 2020
USD

Revenue (FY, 2020)

28.9m

Gross profit (FY, 2020)

26.2m

Gross profit margin (FY, 2020), %

90.8%

Net income (FY, 2020)

(46.0m)

EBIT (FY, 2020)

(24.5m)

Market capitalization (18-Sept-2020)

397.8m

Closing stock price (18-Sept-2020)

3.5

Cash (30-Jun-2020)

12.3m
MEI Pharma's current market capitalization is $397.8 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

23.2m1.6m4.9m28.9m

Cost of goods sold

5.0m3.4m4.3m2.7m

Gross profit

18.2m(1.8m)652.0k26.2m

Gross profit Margin, %

78%(109%)13%91%
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

1.1m17.2m4.5m283.0k358.0k433.0k488.0k2.0m1.2m1.2m1.0m1.2m

Cost of goods sold

1.1m1.8m1.1m618.0k728.0k930.0k989.0k1.0m1.2m688.0k641.0k860.0k

Gross profit

2.0k15.4m3.4m(335.0k)(370.0k)(497.0k)(501.0k)1.0m86.0k469.0k367.0k384.0k

Gross profit Margin, %

0%90%75%(118%)(103%)(115%)(103%)51%7%41%36%31%
USDQ1, 2012

Financial Leverage

1.5 x
Show all financial metrics

MEI Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

MEI Pharma Online and Social Media Presence

Embed Graph

MEI Pharma News and Updates

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in MEI Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline - MEIP

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against MEI Pharma, Inc. ("MEI" or the "Company") (NASDAQ: MEIP) and certain of its officers. The class action, filed in United States District Court for the Southern District of...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in MEI Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline - MEIP

NEW YORK, Aug. 27, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against MEI Pharma, Inc. ("MEI" or the "Company") (NASDAQ: MEIP) and certain of its officers. The class action, filed in United States District Court for the Southern District of...

ROSEN, A GLOBALLY RECOGNIZED FIRM, Announces Filing of Securities Class Action Lawsuit Against MEI Pharma, Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm - MEIP

NEW YORK, Aug. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, inclusive (the "Class Period")....

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MEI Pharma, Inc. - MEIP

NEW YORK, July 2, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MEI Pharma, Inc. ("MEI Pharma" or the "Company") (NASDAQ: MEIP). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...

Thinking about buying stock in Adaptimmune Therapeutics, MEI Pharma, Dynavax Technologies, AIM ImmunoTech, or Meridian Bioscience?

NEW YORK, May 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADAP, MEIP, DVAX, AIM, and VIVO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

MEI Pharma to Release 2019 Fiscal Year End Financial Results and Provide Corporate Update on August 28, 2019

The Company will host a conference call and live webcast with the investment community to provide a corporate update the same day at 5:00 p.m.read more
Show more

MEI Pharma Frequently Asked Questions

  • When was MEI Pharma founded?

    MEI Pharma was founded in 2000.

  • Who are MEI Pharma key executives?

    MEI Pharma's key executives are Daniel Gold, Christine A. White and Robert Mass.

  • How many employees does MEI Pharma have?

    MEI Pharma has 40 employees.

  • What is MEI Pharma revenue?

    Latest MEI Pharma annual revenue is $28.9 m.

  • What is MEI Pharma revenue per employee?

    Latest MEI Pharma revenue per employee is $722.8 k.

  • Who are MEI Pharma competitors?

    Competitors of MEI Pharma include Northwest Biotherapeutics, Merrimack Pharmaceuticals and AVEO Pharmaceuticals.

  • Where is MEI Pharma headquarters?

    MEI Pharma headquarters is located at 3611 Valley Centre Dr #500, San Diego.

  • Where are MEI Pharma offices?

    MEI Pharma has an office in San Diego.

  • How many offices does MEI Pharma have?

    MEI Pharma has 2 offices.